AGIO

Agios Pharmaceuticals, Inc.

A biopharmaceutical company in Cambridge, Massachusetts, that develops treatments for rare blood disorders by targeting cellular metabolism. Its main product, PYRUKYND (mitapivat), is an oral medicine for hemolytic anemia in adults with pyruvate kinase deficiency. Founded in 2008 by three cancer researchers, the company takes its name from the Greek word for "holy" — and sold its cancer business in 2021 to focus on rare genetic diseases.

CUSIP: 00847X104HealthcareUS1 holder

Ownership Activity Financials Filings

AGIO

AGIO

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition